RxDoctor Payments Data

Gregory Kane, MD

Pulmonary Disease · Philadelphia, PANPI 1669495289

Payments from drug & device makers

$854in general payments, 2019–2025

Across 44 payments — averaging $19.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$409
  • Genentech USA, Inc.$88
  • Boehringer Ingelheim$79
  • Sanofi$50
  • AstraZeneca$43
  • Baxter Healthcare$32
  • plus $153 from 7 others

What the payments were for

  • Food & beverage$83398%
  • Education$212%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$854 in reported general payments places this provider in the 40th percentile of 703 pulmonary disease providers in Pennsylvania.

See all pulmonary disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$103,605
Medicare patients
306
Services billed
813

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NucalaMepolizumab33$188,886
Fasenra PenBenralizumab30$168,710
Dupixent PenDupilumab44$158,389
Dupixent SyringeDupilumab28$104,036
Trelegy ElliptaFluticasone/Umeclidin/Vilanter128$101,187
Breo ElliptaFluticasone/Vilanterol197$83,732
Pirfenidone24$81,977
Fluticasone-SalmeterolFluticasone Propion/Salmeterol116$25,496
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr51$22,855
Arnuity ElliptaFluticasone Furoate48$13,971
Spiriva RespimatTiotropium Bromide16$13,866
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$13,734
EliquisApixaban19$11,842
XareltoRivaroxaban12$8,409
Albuterol Sulfate HfaAlbuterol Sulfate202$7,386

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKNucala, Trelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$409$410,632457 claims
AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler$43$24,49059 claims
Boehringer IngelheimSpiriva Respimat$79$13,86616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 703 pulmonary disease providers in Pennsylvania.

Other pulmonary disease in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →